Omalizumab antibody | AbD20760
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti omalizumab (clone AbD20760) at a concentration of 2 μg/ml, followed by an HRP-labeled anti His tag in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with various antigens. For IgE/drug complex antigen, human IgE (HCA171) was immobilized to the plate. After washing and blocking, omalizumab was added. After further incubation and washing steps, detection was performed using Human anti omalizumab (clone AbD20760) titrated to the given concentrations in PBST, followed by an HRP-labelled anti-His tag in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
A microtiter plate was coated over night with human IgE (HCA171) at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of omalizumab. Detection was performed using Human anti omalizumab (clone AbD20760) at a concentration of 2 µg/ml, followed by an HRP-labelled anti-His tag in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate
Human anti Omalizumab (Drug/Target Complex)
Anti-omalizumab drug-target complex antibody specifically recognizes the omalizumab-hIgE complex exclusively and detects omalizumab or biosimilars only when bound to human IgE. This antibody is in monovalent Fab format and is suitable for a PK antigen capture format assay to detect bound drug.
- Product Type
- Monoclonal Antibody
- Clone
- AbD20760
- Isotype
- HuCAL Fab monovalent
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA238 | E | 0.1 mg |
|
Omalizumab (brand name Xolair®) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.
Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.
Human anti Omalizumab, clone AbD20760 is a Type 3 anti-idiotypic antibody that binds specifically to the drug/IgE complex. Clone AbD20760 does not recognise free omalizumab or free human IgE. Clone AbD20760 may be used to detect omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in serum from patients.
Other Type 3 (HCA237) and Type 1 (HCA235, HCA236) antibodies to omalizumab are also available from Bio-Rad in IgG1 and Fab formats. This range of anti omalizumab antibodies forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.
Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.
Human anti Omalizumab, clone AbD20760 is a Type 3 anti-idiotypic antibody that binds specifically to the drug/IgE complex. Clone AbD20760 does not recognise free omalizumab or free human IgE. Clone AbD20760 may be used to detect omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in serum from patients.
Other Type 3 (HCA237) and Type 1 (HCA235, HCA236) antibodies to omalizumab are also available from Bio-Rad in IgG1 and Fab formats. This range of anti omalizumab antibodies forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.
Product Details
- Product Form
- A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
- Preparation
- Metal chelate affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Omalizumab.
- Affinity
- The monovalent intrinsic affinity of HCA238 was measured as Kd = 0.58 nM by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
His-tag is a registered trademark of EMD Biosciences. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Omalizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in an indirect ELISA to detect the omalizumab/IgE complex or to detect omalizumab bound to immobilized IgE.
Protocol: PK antigen capture ELISA to measure bound drug exclusively
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Omalizumab | HCA235 | E | 0.1 mg |
|
|
| Human anti Omalizumab | HCA236 | E | 0.1 mg |
|
|
| Human anti Omalizumab (Drug/Target Complex) | HCA237 | E | 0.1 mg |
|
|
| Rat anti DYKDDDDK Tag:HRP | MCA4764P | E P WB | 0.1 mg |
|
|
| Mouse anti Penta Histidine Tag:HRP | MCA5995P | E WB | 125 µl |
|
Product Specific References
References for Omalizumab antibody
-
Harth, S. et al. (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.
MAbs. 11 (1): 178-90.
